Pfizer Inc. (PFE)

43.07
0.19 0.44
NYSE : Health Technology
Prev Close 42.88
Open 42.82
Day Low/High 42.82 / 43.33
52 Wk Low/High 35.87 / 46.47
Volume 21.66M
Avg Volume 21.16M
Exchange NYSE
Shares Outstanding 5.55B
Market Cap 238.06B
EPS 1.90
P/E Ratio 22.51
Div & Yield 1.44 (3.27%)

Latest News

Fed Up, Yet?

The narrative in the market is that we are waiting for the Fed decision on Wednesday -- but of course it's not that clear cut is it?

Stocks End Slightly Higher in Cautious Trading Ahead of Federal Reserve Meeting

Stocks End Slightly Higher in Cautious Trading Ahead of Federal Reserve Meeting

Stocks end moderately ahead as investors are adopting a cautious stance heading into this week's Federal Reserve meeting.

Bulls Walk the Market Up Slowly, but Keep One Eye on Fed

Bulls Walk the Market Up Slowly, but Keep One Eye on Fed

I'm inclined to add to Disney on today's weakness.

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.

UniQure Jumps on Report It's Exploring a Possible Sale

UniQure Jumps on Report It's Exploring a Possible Sale

A report says the biotechnology company is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.

Pfizer To Acquire Array BioPharma

Pfizer To Acquire Array BioPharma

- Proposed acquisition strengthens Pfizer's innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term

Pfizer To Acquire Array BioPharma

Pfizer To Acquire Array BioPharma

Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc.

How to Invest in Stocks: 14 Keys to Remember

How to Invest in Stocks: 14 Keys to Remember

Larry Swedroe lays out the fundamental truths of investing -- for beginners.

Pfizer Announces Results From XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study To Evaluate Methotrexate Withdrawal With A JAK Inhibitor

Pfizer Announces Results From XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study To Evaluate Methotrexate Withdrawal With A JAK Inhibitor

Pfizer Inc. (NYSE:PFE) announced today positive results from ORAL Shift, a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis (RA).

Great News In An Oversold Market: Cramer's 'Mad Money' Recap (Friday 6/7/19)

Great News In An Oversold Market: Cramer's 'Mad Money' Recap (Friday 6/7/19)

It was a great week for stocks, says Jim Cramer. And he's got your game plan for next week.

PFIZER INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates The Officers And Directors Of Pfizer Inc. - PFE

PFIZER INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates The Officers And Directors Of Pfizer Inc. - PFE

NEW ORLEANS, June 7, 2019 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.

PayPal, Tesla, Pfizer: 'Mad Money' Lightning Round

PayPal, Tesla, Pfizer: 'Mad Money' Lightning Round

Jim Cramer takes a look at PayPal, Tesla, Pfizer, Americold Realty Trust, Continental Resources, United Natural Foods, Cintas, Splunk and more.

Jeff Settleman, Ph.D., Joins Pfizer To Lead Oncology Research & Development

Jeff Settleman, Ph.D., Joins Pfizer To Lead Oncology Research & Development

Pfizer Inc. (NYSE: PFE) announced today that Jeff Settleman, Ph.

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #16 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Despite being ranked lower than the median among analyst picks of the Dow, Pfizer Inc ranks better than the median among analyst picks for the broader S&P 500 index components, claiming the #205 spot out of 500.

Pfizer Announces Top-Line Results From Phase 3 Trial Of LYRICA® (pregabalin) In Primary Generalized Tonic-Clonic Seizures

Pfizer Announces Top-Line Results From Phase 3 Trial Of LYRICA® (pregabalin) In Primary Generalized Tonic-Clonic Seizures

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA ® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary...

Pfizer Gains After Being Named 'Top Pick' by Credit Suisse

Pfizer Gains After Being Named 'Top Pick' by Credit Suisse

Shares of Pfizer rise Thursday after the drugmaker is named a 'top pick' at Credit Suisse following a meeting the analysts had with Pfizer's management team.

Pfizer Oncology To Showcase New Data From Innovative Science That Address Patient Needs At ASCO 2019 Annual Meeting

Pfizer Oncology To Showcase New Data From Innovative Science That Address Patient Needs At ASCO 2019 Annual Meeting

Pfizer Inc. (NYSE:PFE) will present data across its industry-leading oncology portfolio, covering multiple tumor types and mechanisms of action at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from May 31-June 4,...

Pfizer Announces Positive Top-Line Results From Phase 3 Study Of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), In Patients Aged 12 And Older With Moderate To Severe Atopic Dermatitis

Pfizer Announces Positive Top-Line Results From Phase 3 Study Of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), In Patients Aged 12 And Older With Moderate To Severe Atopic Dermatitis

Pfizer Inc. (NYSE: PFE) announced today positive top-line results from a Phase 3 pivotal study (B7451012) evaluating the efficacy and safety of its investigational oral Janus kinase 1 (JAK1) inhibitor, abrocitinib (PF-04965842), in patients aged 12 and...

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Teva Falls as Drugmakers Alleged to Have Artificially Inflated Prices

Attorneys general from 44 states allege the nation's largest generic drugmakers conspired to artificially inflate and manipulate prices for more than 100 different generic drugs.

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

Stock Selloff, Trade War, Teva, Take-Two and Oil Prices - 5 Things You Must Know

U.S. stock futures fall sharply after China vows to stand its ground in the escalating trade war with the United States; oil prices surge after Saudi Arabia alleges two of its tankers were victims of a 'sabotage attack,' Teva and other drugmakers are alleged to have conspired to artificially inflate and manipulate prices for generic drugs.

Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales

Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales

Shares of Puma Biotechnology plunge after the company reveals that more patients than expected have discontinued treatment with its breast cancer drug, Nerlynx, prompting several analyst downgrades.

Sweet Taste of Fear

Sentiment's shifting, we're getting oversold and it looks like fear and panic are creeping in -- that's the way it should be.

Pfizer Acquires Clinical-Stage Biotech Therachon

Pfizer Acquires Clinical-Stage Biotech Therachon

Pfizer (NYSE: PFE) today announced that it has entered into a definitive agreement to acquire all the shares of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the...

European Commission Approves LORVIQUA® (lorlatinib) For Certain Adult Patients With Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

European Commission Approves LORVIQUA® (lorlatinib) For Certain Adult Patients With Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer

Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) granted conditional marketing authorization for LORVIQUA ® (lorlatinib, available in the U.

Pfizer Gets FDA Approval for $225,000 Heart Disease Drug

Pfizer Gets FDA Approval for $225,000 Heart Disease Drug

The FDA approves Pfizer's treatment for a rare form of heart disease.

TheStreet Quant Rating: B (Buy)